Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453642 · ClinicalTrials.gov registry record · NA
Evaluation of a Simple-Prep Controlled Embolic
A NA study of Renal Cell Carcinoma and Bone Tumor, sponsored by Fluidx Medical Technology.
- Active
- Registry status
- NA
- Development phase
- 114
- Enrollment target
- 20
- Study locations
NCT06453642 is a NA study of Renal Cell Carcinoma and Bone Tumor that is active but no longer recruiting, run by Fluidx Medical Technology. The registered enrollment target is 114 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06453642, a NA study of Renal Cell Carcinoma and Bone Tumor, is active but no longer recruiting, sponsored by Fluidx Medical Technology.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 114 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Conditions Studied
Interventions
- DEVICE GPX® Embolic Device
Study Locations (20)
New York
- Albany Medical Center - Albany
- Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Ontario
- St. Michael's Hospital - Toronto
- Toronto General Hosptial - Toronto
- Mount Sinai Hospital Toronto - Toronto
North Carolina
- University of North Carolina - Chapel Hill
- Atrium Health Carolinas Medical Center - Charlotte
Texas
- University of Texas Southwestern - Dallas
- MD Anderson Cancer Center - Interventional Radiology - Houston
Other
- Auckland City Hospital - Auckland
- Christchurch Hospital - Christchurch
California
- University of California San Diego Altman Clinical and Translation Research Institute - La Jolla
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453642
The ClinicalTrials.gov registry entry for NCT06453642 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (53% lower). The listed sponsor is Fluidx Medical Technology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which GPX® Embolic Device is the first listed.
NCT06453642 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Ontario, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06453642 about?
NCT06453642 is a clinical study titled "Evaluation of a Simple-Prep Controlled Embolic". The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
What is the current status of trial NCT06453642?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 114 participants. The study started on 2024-11-18. Estimated completion is 2026-09.
What conditions does trial NCT06453642 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Bone Tumor, Embolization, Vascular Tumor, Renal Angiomyolipoma.
What interventions are being tested in trial NCT06453642?
The interventions under investigation include: GPX® Embolic Device (DEVICE).
Who is sponsoring clinical trial NCT06453642?
This trial is sponsored by Fluidx Medical Technology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06453642 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
RECRUITING · NA
-
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
RECRUITING · NA
-
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.